The Korean Journal of Gastroenterology (대한소화기학회지)

The Korean Society of Gastroenterology (대한소화기학회)
권호 표지

The Assessment of Toxic Liver Injury

독성 간손상의 평가

Kim, Dong-Joon
김동준

  • Published : 20090100
⟨ Previous Next ⟩

Abstract

Liver injury due to prescription and nonprescription medications is a growing medical, scientific and public health problem. Drug-induced liver injury (DILI) is the single most common reason for regulatory actions, including failure of approval, removal from the marketplace and restriction of prescription. Worldwide, the estimated annual incidence rate of DILI is 13.9-24.0 per 100,000 inhabitants. At the same time, there is increasing concern about the potential risk for hepatotoxicity from complementary and alternative medicines (CAM) including herbal products because they are unregulated and not standardized with regard to their contents. Determining hepatotoxicity remains a major challenge in clinical practice due to a lack of reliable markers. The RUCAM/CIOMS scale have been proposed to establish a causal relationship between offending drug and liver injury. The efforts of Drug-Induced Liver Injury Network (DILIN, USA) directed toward the development of an abridged instrument in evaluating suspected drug-induced hepatotoxicity were presented at the National Institute of Health (NIH) Workshop, titled “Drug-induced liver injury: Standardization of nomenclature and causality assessment”, December, 2008. The main contents of the presentations and discussions at the NIH workshop are introduced in this article. This fine-tuned operations of RUCAM/CIOMS scale would enable a more confident assessment of causality and facilitate the collection of bona fide cases of drug-induced hepatotoxicity in Korea. Several demanding tasks for the near future in Korea are also proposed at the end.

Keywords

References

  1. Zimmerman HJ. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams&Wilkins, 1999.
  2. Kaplowitz N. Drug-induced liver disorders: introduction and overview. In: Kaplowitz N, Deleve LD, eds. Drug-induced liver disease. New York: Marcel Dekker Inc., 2003.
  3. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-485. https://doi.org/10.1056/NEJMra021844
  4. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-739. https://doi.org/10.1056/NEJMra052270
  5. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006;43:618-631. https://doi.org/10.1002/hep.21095
  6. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001;24:483-490. https://doi.org/10.2165/00002018-200124070-00001
  7. Guidance for Industry Drug-Induced Liver Injury: premarketing clinical evaluation. http://www.fda.gov/OHRMS/DOCKETS/ 98fr/07d-0396-gdl0001.pdf.
  8. Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002;36:451-455. https://doi.org/10.1053/jhep.2002.34857
  9. Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999;319:1541.
  10. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;338:916-917. https://doi.org/10.1056/NEJM199803263381314
  11. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512-521. https://doi.org/10.1016/j.gastro.2005.05.006
  12. Kim DJ, Jang MK, Hahn TH, et al. A prospective nationwide study of toxic liver injury in Korea. Hepatology 2008;48(suppl): 470A.
  13. Hoofnagle JH. Drug-induced liver injury network (DILIN). Hepatology 2004;40:773. https://doi.org/10.1002/hep.20445
  14. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-1934. https://doi.org/10.1053/j.gastro.2008.09.011
  15. Fontana RJ, Watkins PB, Bonkovsky HL, et al. for the DILIN Study Group. Drug Induced Liver Injury Network (DILIN) porspective study: rationale, design and conduct. Drug Safety 2009;32:1-14. https://doi.org/10.2165/00002018-200932010-00001
  16. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11: 272-276. https://doi.org/10.1016/0168-8278(90)90124-A
  17. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330 https://doi.org/10.1016/0895-4356(93)90101-6
  18. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336. https://doi.org/10.1016/0895-4356(93)90102-7
  19. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-310. https://doi.org/10.1053/jhep.2001.21083
  20. Seeff L. Issues of nomenclature and causality. Drug-Induced Liver Injury: Standardization of Nomenclature and Causality Assessment. NIH Workshop, December 1-2, 2008, Bethesda, MD. http://www3.niddk.nih.gov/fund/other/diliworkshop2008.
  21. Drug-Induced Liver Injury: Standardization of Nomenclature and Causality Assessment. NIH Workshop, December 1-2, 2008, Bethesda, MD. http://www3.niddk.nih.gov/fund/other/diliworkshop2008
  22. RUCAM Manual of Operations. Drug-Induced Liver Injury: Standardization of Nomenclature and Causality Assessment. NIH Workshop, December 1-2, 2008, Bethesda, MD. http://www3.niddk.nih.gov/fund/other/diliworkshop2008
  23. Takikawa H, Onji M. A proposal of the diagnostic scale of drug-induced liver injury. Hepatol Res 2005;32:250-251. https://doi.org/10.1016/j.hepres.2005.05.007
  24. Maria VA, Victorino RM. Diagnostic value of specific T-cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997;41:534-540. https://doi.org/10.1136/gut.41.4.534
  25. Maria VA, Victorino RM. Immunological investigation in hepatic drug reactions. Clin Exp Allergy 1998;28(suppl 4): 71-77. https://doi.org/10.1046/j.1365-2222.1998.028s5071.x
  26. Berg PA, Becker EW. The lymphocyte transformation test-a debated method for the evaluation of drug allergic hepatic injury. J Hepatol 1995;22:115-118. https://doi.org/10.1016/0168-8278(95)80270-3
  27. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664-669. https://doi.org/10.1002/hep.510260319
  28. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33:123-130. https://doi.org/10.1053/jhep.2001.20645
  29. Larrey D. European hepatotoxicity network: France. Drug- Induced Liver Injury: Standardization of Nomenclature and Causality Assessment. NIH Workshop, December 1-2, 2008, Bethesda, MD. http://www3.niddk.nih.gov/fund/other/diliworkshop2008